Clinical Study
Serum NGAL in Critically Ill Children in ICU from a Single Center in Egypt
Table 1
Laboratory investigations of study groups regarding liver and kidney functions.
| Parameter | Control | Patients | Test of significance | |
| Total bilirubin (mg/dL) | | | | | Median | 0.4 | 0.5 | 1.25b | 0.210 | Range | (0.3–0.8) | (0.3–23.4) | Direct bilirubin (mg/dL) | | | | | Median | 0.1 | 0.5 | 0.99b | 0.321 | Range | (0.1–0.2) | (0.1–12.9) | ALT (U/L) | | | | | Median | 31 | 45.5 | 1.11b | 0.26 | Range | (12–42) | (9–133) | AST (U/L) | | | | | Median | 38 | 55.6 | 3.007b | 0.003* | Range | (5–55) | (18–1207) | Albumin (g/dL) | | | | | X′ ± SD | (3.907 ± 0.371) | (3.36 ± 0.618) | 3.245a | 0.002* | TP (g/dL) | | | | | X′ ± SD | (6.8 ± 0.442) | (5.7 ± 0.868) | 4.47a | 0.001* | Urea (mg/dL) | | | | | Median | 25.8 | 35.5 | 3.42b | 0.001* | Range | (15–37) | (15–116) | Creatinine (mg/dL) | | | | | X′ ± SD | 0.65 ± 0.22 | 0.68 ± 0.22 | 0.38a | 0.69 | WBCs (×103/cmm) | 12.1 (6.1–14.1) | 13.1 (2.1–56.2) | 0.64b | 0.51 | Hb (g/dL ) | 12.5 (9.5–15.5) | 10.5 (6.6–18) | 6.26b | 0.001* | Platelet (×109/cmm) | 250 (180–340) | 222 (35–1008) | 0.49b | 0.62 | NGAL-0 (ng/mL) | 54 (44–141) | 88.5 (34–210) | 2.47b | 0.01* |
|
|
Test of significance: at-test; bMann-Whiney test; *significant.
|